0001090872-25-000087
SEC filingAgilent's 2025 revenue grew 7% to $6.95B, driven by all segments, with operating margin down 160 bps to 21.3% due to tariffs and mix.
Agilent Technologies, Inc. is a global leader in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The company serves customers across pharmaceutical and biopharmaceutical, diagnostics and clinical, academic and government, chemicals and advanced materials, food, and environmental and forensics markets.
Following a November 2024 organizational restructuring, Agilent operates three reportable segments. The Life Sciences and Diagnostics Markets segment combines the former Diagnostics and Genomics segment with liquid chromatography and liquid chromatography mass spectrometry instrument platforms. It provides active pharmaceutical ingredients for oligo-based therapeutics, reagents, instruments, software, and consumables for clinical and life sciences research. The Agilent CrossLab segment brings together chemistries and supplies, laboratory automation, and software and informatics; it offers an extensive services and consumables portfolio including repairs, maintenance, training, compliance support, software as a service, asset management, and consulting. The Applied Markets segment includes gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy, and vacuum divisions, providing application-focused solutions for identification, quantification, and analysis of physical and biological properties.
Key product areas include liquid chromatography systems and components; mass spectrometry systems (single quadrupole, triple quadrupole, time-of-flight, quadrupole time-of-flight); cell analysis platforms (Seahorse, xCELLigence, Novocyte, BioTek); pathology solutions (CoverStainer, Artisan, Dako Omnis, Autostainer); companion diagnostics; genomics reagents (next-generation sequencing target enrichment, microarrays); contract development and manufacturing organization (CDMO) including BIOVECTRA and nucleic acid solutions; biomolecular analysis; gas chromatography; spectroscopy (atomic absorption, ICP-MS, ICP-OES, FTIR, Raman); vacuum technology; and remarketed instruments.
Agilent sells through a multi-channel approach: direct sales (primarily for large accounts), distributors, resellers, manufacturers' representatives, and electronic commerce. In fiscal year 2025, the Life Sciences and Diagnostics Markets segment had approximately 22,200 customers, Agilent CrossLab had approximately 59,700 customers (many overlapping with other segments), and Applied Markets had approximately 17,200 customers. No single customer concentration is disclosed; a significant number of CrossLab customers are also customers of other segments.
The analytical instrument markets are characterized by evolving standards and intense competition. Principal competitors include AB Sciex (Danaher), Avecia (Nitto Denko), Bruker, Leica Biosystems (Danaher), Roche Ventana (Roche), Shimadzu, Thermo Fisher Scientific, Twist Bioscience, Waters Corporation, PerkinElmer, and numerous niche service providers. Agilent competes on product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage, and price.
Agilent's strategy is market-focused and customer-centric. Key pillars include: driving innovation through research and development to improve product performance and ease of use; expanding application spaces via new product enhancements; forming strategic partnerships, especially in companion diagnostics; and achieving operational excellence through advanced manufacturing techniques and supply chain management. The company also emphasizes digital and virtual support technologies and a vendor-neutral consumables portfolio to serve customers regardless of instrument brand.
As of October 31, 2025, Agilent employed approximately 18,100 people worldwide: 7,100 in the Americas, 4,400 in Europe, and 6,600 in Asia Pacific. Segment headcounts: Life Sciences and Diagnostics Markets ~6,300; Agilent CrossLab ~7,400; Applied Markets ~2,500; and Global Infrastructure ~1,900. The company invests in employee engagement, development, health and safety, and community involvement.
Agilent's net revenue for fiscal year 2025 increased 7% to $6,948 million, compared to $6,510 million in 2024. The overall effect of foreign currency movements had no impact on revenue growth. The BIOVECTRA acquisition contributed approximately 2 percentage points to total revenue growth. Product revenue increased 6%, while services and other revenue grew 9%. Net income rose to $1,303 million from $1,289 million in 2024, favorably impacted by several tax benefits including a $57 million benefit from an intra-entity transfer of assets, a $29 million benefit from foreign-derived intangible income, and a $28 million benefit from the release of tax reserves. Total gross margin declined 2 percentage points to 52.4%, driven by higher tariffs, shipping costs, and unfavorable business mix (including lower gross margin from the specialty CDMO business), partially offset by higher sales volume and targeted pricing increases. Operating margin decreased 2 percentage points to 21.3%, impacted by the same factors plus higher transformational initiatives and wages.
The Life Sciences and Diagnostics Markets segment posted the strongest growth, with revenue up 11% to $2,726 million, including a 5 percentage point contribution from the BIOVECTRA acquisition. Growth was led by the pharmaceutical market, driven by the contract development and manufacturing organization, liquid chromatography, and liquid chromatography mass spectrometry businesses. The diagnostics and clinical market also grew strongly, led by companion diagnostics and pathology. Gross margin for the segment decreased 2 percentage points to 52.3% due to tariffs, shipping costs, and unfavorable mix. Operating margin was flat at 19.7%.
The Agilent CrossLab segment revenue increased 6% to $2,908 million, with growth across most end markets, led by pharmaceutical, chemical and advanced materials, and food. Gross margin decreased 1 percentage point to 55.4% due to tariffs, shipping costs, and higher wages, partially offset by higher volume and price increases. Operating margin decreased 1 percentage point to 32.5%.
The Applied Markets segment revenue increased 1% to $1,314 million, with significant growth in food and pharmaceutical markets partially offset by declines in chemical and advanced materials and academic and government markets. Gross margin decreased 1 percentage point to 54.4% due to tariffs, shipping costs, and unfavorable currency. Operating margin decreased 1 percentage point to 22.9%.
Management remains optimistic about long-term growth in key end markets, noting that after an extended period of constrained capital spending, many customers' ability to spend capital budgets has begun to normalize, with the exception of customers receiving U.S. federal government funding. While recent tariff changes adversely impacted cost of revenue beginning in the second half of fiscal year 2025, management expects to substantially mitigate the impact during fiscal year 2026 through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives. The company expects income taxes to increase in fiscal year 2026 due to Pillar Two top-up taxes and the implementation of the One Big Beautiful Bill Act. Capital expenditures for fiscal year 2026 are anticipated to be approximately $500 million, primarily for expansion of manufacturing capacity for nucleic acid-based therapeutics in Frederick, Colorado.
As of October 31, 2025, Agilent held $1.789B in cash and cash equivalents, up from $1.329B a year earlier. Total debt stood at $3.354B ($304M short-term, $3.050B long-term), compared to $3.390B in 2024. Shareholders' equity increased to $6.741B from $5.898B, driven by net income and other comprehensive income. Inventory rose to $1.025B from $972M, reflecting higher finished goods and purchased parts. Deferred revenue (contract liabilities) grew to $803M from $701M, indicating a growing backlog of unfulfilled performance obligations.
Agilent disclosed $219M in future minimum rents payable under non-cancelable operating leases with initial terms exceeding one year. Of this, $51M is due within one year, $71M in years 1-3, and $97M beyond three years. Additionally, the company reported $437M in estimated revenue expected to be recognized for remaining performance obligations with original terms of more than one year, the majority of which is expected to be recognized over the next 12 months. No other material purchase commitments (e.g., supply or capacity) were disclosed in the Notes.
In fiscal 2025, Agilent repurchased 3.397M shares for $428M (including excise tax), compared to $1.160B in 2024. Dividends totaled $282M ($0.992 per share), up from $274M ($0.944 per share) in 2024. Capital expenditures were $407M (5.9% of sales), up from $378M in 2024, primarily for expansion of the Frederick, CO facility. Debt activity was minimal: $4M in proceeds and $3M in repayments, with net short-term debt decreasing by $42M. No new debt was issued or repaid in material amounts.
Agilent reports three segments: Life Sciences and Diagnostics Markets ($2.726B revenue, +10.5% YoY), Agilent CrossLab ($2.908B, +5.9%), and Applied Markets ($1.314B, +1.3%). Geographic revenue: Americas $2.806B, Europe $1.923B, Asia Pacific $2.219B. Revenue by end market: Pharmaceutical and Biopharmaceutical $2.507B, Chemicals and Advanced Materials $1.561B, Diagnostics and Clinical $1.029B, Food $637M, Academia and Government $540M, Environmental and Forensics $674M. Instrumentation revenue was $2.427B; non-instrumentation and other was $4.521B.
Agilent's Item 1A risk factors are extensive, reflecting its global footprint, regulatory exposure, and technology-intensive operations. Key themes include macroeconomic sensitivity, geopolitical tensions, expanding regulatory burdens, and emerging AI-related risks.
Agilent highlights sensitivity to global economic conditions, with slower growth, inflation, and rising interest rates potentially reducing demand and pressuring margins. The company notes limited market visibility and difficulty forecasting quarterly orders, exacerbated by seasonal patterns that may not materialize as expected. Pricing pressure in a downturn could further erode operating margins given the fixed nature of many costs.
International revenue accounts for a majority of sales, exposing Agilent to currency fluctuations (hedged partially but not fully), trade disruptions, and political instability in regions such as Ukraine, the Middle East, and China. Tariffs, particularly US-China trade measures, are flagged as a material risk that may require costly operational changes. The company also warns of potential disruptions from instability in its centralized accounting/tax hubs in India and Malaysia.
Regulatory risks are broad. Agilent faces FDA oversight for many products, and failure to comply could result in warning letters, product seizures, or criminal penalties. Data privacy regulation (GDPR, China PIPL, CCPA) is increasingly stringent, with fines up to 4% of revenue. New AI-related legal frameworks add another layer of compliance burden. Environmental regulations, including the Toxic Substances Control Act, and government contracting rules also present liability.
Agilent is integrating AI into operations and products, but warns of risks from biased outputs, intellectual property leakage, and regulatory penalties. Cybersecurity remains critical; the SolarWinds attack is cited as an example. Dependence on centralized IT systems and third-party providers (contract manufacturers, logistics) creates single points of failure. Manufacturing consolidation increases vulnerability to catastrophic events (earthquakes, fires) in California and Japan, with limited insurance coverage.
Acquisition integration is a recurring risk—acquired businesses may not achieve expected synergies, and goodwill impairment could result. Tax risks include changes in US and Singapore tax laws, possible non-renewal of Singapore incentives, and uncertain outcomes from multi-jurisdiction audits. The company carries $3.4 billion in debt, and any downgrade or covenant breach could impact liquidity. Dividend payments, though consistent since 2012, are not guaranteed.
The 2025 10-K risk factors are comprehensive and detailed. Material updates include explicit references to AI risks, expanded discussion of tariffs and trade policy, and heightened focus on regulatory fragmentation. The filing reflects a company navigating a complex global environment with multiple concurrent threats.